Abstract
Purpose: To systematically review the value of serum inflammatory markers to diagnose diabetic foot osteomyelitis (DFO). Study selection: Studies to diagnose DFO using biomarkers erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT), interleukins (IL-2, IL-6, IL-8) and tumor necrosis factor alfa (TNF) were retrieved from EMBASE and PubMed with no language restrictions through July 2014. Data extraction: We summarized clinical characteristics of the studies and used bivariate random effects models and summary receiver operating characteristic curves to estimate sensitivity and specificity for each marker. Data synthesis: A total of 8 qualifying studies were included in our meta-analysis. Bivariate pooled sensitivity and specificity of the 6 studies examining ESR were 0.81 (95% CI 0.71-0.88) and 0.90 (95% CI 0.75-0.96) respectively. Due to the paucity of data, models did not converge for the other biomarkers. Conclusions: From the inflammatory markers, ESR appears to be the best laboratory test to identify patients with DFO.
Keywords: Diabetic foot, osteomyelitis, biomarkers, diabetic foot infection, diagnosis, erythrocyte sedimentation rate, c-reactive protein, procalcitonin.
Current Diabetes Reviews
Title:The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis
Volume: 12 Issue: 4
Author(s): Suzanne Aura Victoria van Asten, Edgar Joseph Geradus Peters, Yin Xi and Lawrence Alfred Lavery
Affiliation:
Keywords: Diabetic foot, osteomyelitis, biomarkers, diabetic foot infection, diagnosis, erythrocyte sedimentation rate, c-reactive protein, procalcitonin.
Abstract: Purpose: To systematically review the value of serum inflammatory markers to diagnose diabetic foot osteomyelitis (DFO). Study selection: Studies to diagnose DFO using biomarkers erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT), interleukins (IL-2, IL-6, IL-8) and tumor necrosis factor alfa (TNF) were retrieved from EMBASE and PubMed with no language restrictions through July 2014. Data extraction: We summarized clinical characteristics of the studies and used bivariate random effects models and summary receiver operating characteristic curves to estimate sensitivity and specificity for each marker. Data synthesis: A total of 8 qualifying studies were included in our meta-analysis. Bivariate pooled sensitivity and specificity of the 6 studies examining ESR were 0.81 (95% CI 0.71-0.88) and 0.90 (95% CI 0.75-0.96) respectively. Due to the paucity of data, models did not converge for the other biomarkers. Conclusions: From the inflammatory markers, ESR appears to be the best laboratory test to identify patients with DFO.
Export Options
About this article
Cite this article as:
Victoria van Asten Aura Suzanne, Geradus Peters Joseph Edgar, Xi Yin and Lavery Alfred Lawrence, The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis, Current Diabetes Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573399811666150713104401
DOI https://dx.doi.org/10.2174/1573399811666150713104401 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
(Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Influence of Usnic Acid and its Derivatives on the Activity of Mammalian Poly(ADP-ribose)polymerase 1 and DNA Polymerase β
Medicinal Chemistry The ERK and p38MAPK Pathways as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Tale of Two Eras: Mining Big Data from Electronic Health Records to Determine Limb Salvage Rates with Podiatry
Current Diabetes Reviews Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Mesenchymal Stromal Cells in Rheumatoid Arthritis: Biological Properties and Clinical Applications
Current Stem Cell Research & Therapy Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design Gene Expression Profiling as a Tool for Positional Cloning of Genes- Shortcut or the Longest Way Round
Current Genomics Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Diagnostic Value of 99m Tc- Labeled-Ubiquicidin 29-41 (99m Tc-UBI) Scan in the Diagnosis of Vertebral Osteomyelitis
Current Medical Imaging Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Development ofNovel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions
Endocrine, Metabolic & Immune Disorders - Drug Targets